Fortrea is executing a turnaround centered on gross margin recovery (20.5% in 2026Q2, up from 16.3% in 2026Q1) and a sharp debt reduction (D/E fell from 2.13 to 0.15), yet revenue continues to decline (-4.5% YoY) and cumulative losses have eroded equity to $52...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $0.23+27.5% vs $0.18 | $678M+4.7% vs $648M |
Q2 2026 May 5, 2026 | $0.16+433.3% vs $0.03 | $637M+1.3% vs $629M |
Q1 2026 Feb 26, 2026 | $0.09-43.8% vs $0.16 | $661M-0.7% vs $665M |
Q4 2025 Nov 5, 2025 | $0.12-25.0% vs $0.16 | $701M+5.4% vs $665M |
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees.
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September:
Fortrea (NASDAQ:FTRE) signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million.
Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets
Benchmark FTRE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Fortrea Holdings Inc. (FTRE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.52 | $1.86B | -1.81 | 1% | -36.21% | -102.41% | — | |
| $267.86 | $44.09B | 34.17 | 5.87% | 8.1% | 21.51% | — | |
| $277.33 | $13.36B | -95.30 | -0.85% | -5.96% | -7.63% | — | |
| $617.15 | $17.23B | 40.39 | 19.97% | 17.67% | 110.15% | — | |
| $25.00 | $1.29B | 25.25 | -2.67% | 6.04% | 4.95% | — | |
| $163.90 | $12.55B | 56.52 | -0.37% | 3.99% | 3.54% | — |
Fortrea Holdings Inc. (FTRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Fortrea Holdings Inc. (FTRE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jul 14, 2026·SEC
Jun 26, 2026·SEC
Get notified when FTRE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Fortrea Holdings Inc. (FTRE) stock FAQ — growth, dividends, profitability & financials explained
Fortrea Holdings Inc. (FTRE) reported $2.68B in revenue for fiscal year 2025. This represents a 12% decrease from $3.06B in 2021.
Fortrea Holdings Inc. (FTRE) grew revenue by 1.0% over the past year. Growth has been modest.
Fortrea Holdings Inc. (FTRE) reported a net loss of $85.2M for fiscal year 2025.
Fortrea Holdings Inc. (FTRE) has a return on equity (ROE) of -102.4%. Negative ROE indicates the company is unprofitable.
Fortrea Holdings Inc. (FTRE) generated $150.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
